

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **September 1, 2021** Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.php.

Please refer to the September 1, 2021 updates for complete listings of products available by special authorization, restricted benefit/special authorization, step therapy/special authorization, products with changes to criteria for coverage, restricted benefits, added products, new established interchangeable groupings, Least Cost Alternative (LCA) price changes, products with a price change and discontinued products.

Please note that the online Interactive Drug Benefit List (iDBL) at www.ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Product supply shortage addressed for ADBL

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Teva-Budesonide 0.5mg/ml Inhalation Suspension (DIN 02465957) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 20, 2021**. The following grouping was removed from the Critical Supply Product List **August 20, 2021**.

BUDESONIDE

0.5 MG / ML INHALATION SUSPENSION

00002465957	TEVA-BUDESONIDE	TEV	\$ 0.6839
00001978926	PULMICORT NEBUAMP	AZC	\$ 0.9473

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

